Back

Positioning of the topic - The PCSK9 story .. so far

27 August 2017 (11:01 - 11:15)
Organised by:
Congress Presentation Part of: Do we need PCSK9 inhibitors in post-MI patients? Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Francois Mach

University hospitals of Geneva, Geneva (Switzerland)

7 More presentations in this session

Presentation thumbnail
Opening question.
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? PRO
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? CON
Professor H. Drexel (Feldkirch, AT)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO
Professor M. Sabatine (Boston, US)
Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal CON
Professor H. Drexel (Feldkirch, AT)
Video

Access the full session

Session thumbnail
Do we need PCSK9 inhibitors in post-MI patients?

The Event

Event poster

ESC Congress 2017

27 August 2017 11:01 CET
You may be interested in
thumbnail
Congress Presentation
Targeting the PCSK9 pathway: where do novel therapies fit in?
26 August 2022
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources